Salicylic acid

Description

The drug is identified by the SPL code 34089-3. It is presented as a white to off-white, round, biconvex tablet, which is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for use in patients as determined by the prescribing healthcare professional. Currently, there are no specific indications or usage details provided.

There are no known teratogenic or nonteratogenic effects associated with this drug. Healthcare professionals should consider the absence of these effects when evaluating treatment options for their patients.

Dosage and Administration

The patch should be removed from its packaging prior to application. Healthcare professionals should instruct patients to carefully peel away the white film from the patch, taking care to avoid contact with the center of the patch.

The patch is to be applied directly to the affected area, ensuring that it is pressed down vertically with the fingers to secure proper adhesion. The duration of application may vary; the patch can be left in place for either 2 hours or overnight, depending on the specific treatment plan. After the designated time, the patch should be removed gently from the skin.

Contraindications

The use of this product is contraindicated in patients who are concurrently using another topical acne medication, as this may lead to increased skin irritation and dryness. If severe irritation occurs, discontinue use immediately.

Warnings and Precautions

For external use only. It is imperative that healthcare professionals advise patients to avoid ingestion of the product. In the event of accidental swallowing, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Healthcare providers should monitor patients for any signs of irritation. If irritation becomes severe, it is recommended to discontinue use of the product promptly. Regular assessment of the patient's skin condition may be necessary to ensure safety and efficacy during treatment.

Side Effects

Patients should be aware that the product is intended for external use only. In clinical practice, if irritation becomes severe, it is advised to discontinue use immediately. Additionally, patients are encouraged to consult a healthcare professional if they experience severe irritation.

These precautions are essential to ensure the safety and well-being of individuals using the product.

Drug Interactions

Concurrent use of topical acne medications may lead to skin irritation and dryness. It is advisable to avoid the simultaneous application of multiple topical acne treatments or the use of another topical acne medication immediately following the application of the first.

In cases where irritation is experienced, it is recommended to limit the use to one topical acne medication at a time unless otherwise directed by a healthcare professional. Monitoring for signs of skin irritation is advised to ensure patient comfort and treatment efficacy.

Packaging & NDC

Below are the non-prescription pack sizes of Acropass Acne Cure. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

There is no specific pediatric use information available for this medication, including recommended ages, dosing differences, safety concerns, or special precautions for children. Healthcare professionals should exercise caution when considering the use of this medication in pediatric patients due to the absence of relevant data.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients.

Due to the lack of data, it is advisable to closely monitor elderly patients for any potential adverse effects and to consider individual patient factors when determining the appropriateness of therapy.

Pregnancy

The safety of this product during pregnancy has not been established. The use of salicylic acid is contraindicated in pregnancy due to potential risk to the fetus. Pregnant patients or those planning to become pregnant should consult a healthcare provider before using this product to discuss potential risks and benefits.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective treatment and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to fully evaluate the nonclinical toxicology profile.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is important to inform patients about the potential for skin irritation and dryness, particularly if they are using another topical acne medication concurrently or immediately after applying this product.

Patients should be counseled to monitor for any signs of irritation. If irritation becomes severe, they should discontinue use and consult their healthcare provider. Additionally, healthcare providers should emphasize that patients should only use one topical acne medication at a time unless specifically directed otherwise by their doctor. This guidance is crucial to minimize the risk of adverse effects and ensure effective treatment.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers assigned for identification. It is essential to store the product at room temperature to maintain its integrity and efficacy. No special handling requirements are noted; however, standard precautions should be observed to ensure optimal storage conditions.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Acropass Acne Cure, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)